ERBB2 and breast cancer: As a humanized antibody acting against human epidermal growth factor receptor 2 (HER2), trastuzumab has been approved by the FDA to treat metastatic GC, gastroesophageal junction cancer, as well as breast cancer expressing HER2 at very high levels 6, 7, 8.